Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Related Questions
What second line therapy do you use for metastatic thymoma that recurs following CAP?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How would you approach first-line treatment in metastatic NSCLC for a patient with ALK-EML4 V3a/b variant and MSI-high status?
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
